Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen

被引：4

作者：

Wang, Hongyue ^{[1
]}

Ma, Xinchi ^{[2
]}

Zhang, Bin ^{[3
]}

Zhang, Yaotian ^{[2
]}

Han, Ning ^{[2
]}

Wei, Linlin ^{[2
]}

Sun, Chaonan ^{[2
]}

Sun, Shichen ^{[2
]}

Zeng, Xue ^{[2
]}

Guo, Hong ^{[2
]}

Li, Yubing ^{[2
]}

Zhang, Yanyu ^{[2
]}

Zhao, Jiaming ^{[2
]}

Qin, Zilan ^{[2
]}

Liu, Zhuang ^{[2
]}

Zhang, Na ^{[2
]}

机构：

[1] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Sci Res & Acad, Shenyang, Liaoning, Peoples R China

[2] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Breast Radiat Oncol, Shenyang, Liaoning, Peoples R China

[3] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Breast Surg, Shenyang, Liaoning, Peoples R China

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷 / 02期

关键词：

breast cancer; tamoxifen; toremifene; GENETIC POLYMORPHISMS; ESTROGEN-RECEPTOR; CYP2D6; GENOTYPE; METABOLISM; PHARMACOGENETICS; METAANALYSIS; EFFICACY; ALLELES; IMPACT; WOMEN;

D O I：

10.1111/ajco.13571

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose To evaluate the prognosis of estrogen receptor-positive breast cancer patients with CYP2D6*10 mutant genotypes under tamoxifen or toremifen therapy. Methods Estrogen receptor-positive breast cancer patients were selected and CYP2D6*10 genotypes (C/C, C/T, and T/T) were determined by Sanger sequencing. Patients were divided into tamoxifen, toremifene, or tamoxifen + toremifene groups according to prior therapy. The correlation between CYP2D6*10 genotype and disease-free survival was analyzed. Results In total, 293 estrogen receptor-positive breast cancer patients treated with tamoxifen or toremifene between 2008 and 2017 were studied. Median follow-up was 39 months (10-141). Of these, 107 (36.52%), 112 (38.23%), and 74 (25.26%) patients had C/C, C/T, and T/T genotypes, respectively. Genotype was significantly associated with disease-free survival in tamoxifen patients. Patients with C/T and T/T genotypes showed worse disease-free survival than patients with a C/C genotype. Genotype and disease-free survival in toremifene and tamoxifen+toremifene patients were not correlated. Of patients with a C/T genotype, toremifene or tamoxifen+toremifene groups showed better disease-free survival than tamoxifen patients. Although disease-free survival of patients with a T/T genotype in the three groups was not statistically different, tamoxifen patients showed worse disease-free survival. There was no correlation between different treatments and disease-free survival in patients with a C/C genotype. Cox proportional hazard analysis revealed toremifene patients had a better prognosis than tamoxifen patients; toremifene was an independent protective factoremifene for disease-free survival. Conclusions Tamoxifen was less effective in patients with CYP2D6*10 C/T and T/T genotypes. Estrogen receptor-positive breast cancer patients with a CYP2D6*10 mutation genotype have a better prognosis with toremifen than tamoxifen.

引用

页码：E148 / E153

页数：6

共 30 条

[1] Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and*14 (G1758A) alleles among Iranians of different ethnicities [J].

Bagheri, Ali ;

Kamalidehghan, Behnam ;

Haghshenas, Maryam ;

Azadfar, Parisa ;

Akbari, Leila ;

Sangtarash, Mohammad Hossein ;

Vejdandoust, Faramarz ;

Ahmadipour, Fatemeh ;

Meng, Goh Yong ;

Houshmand, Massoud .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :2627-2634

[2] Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy [J].

Blackburn, Heather L. ;

Ellsworth, Darrell L. ;

Shriver, Craig D. ;

Ellsworth, Rachel E. .

CANCER CAUSES & CONTROL, 2015, 26 (03) :319-332

[3] Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis [J].

Chi, Feng ;

Wu, Rong ;

Zeng, Yuecan ;

Xing, Rui ;

Liu, Yang ;

Xu, Zhaoguo .

BREAST CANCER, 2013, 20 (02) :111-122

[4] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J].

Davies, C. ;

Godwin, J. ;

Gray, R. ;

Clarke, M. ;

Darby, S. ;

McGale, P. ;

Wang, Y. C. ;

Peto, R. ;

Pan, H. C. ;

Cutter, D. ;

Taylor, C. ;

Ingle, J. .

LANCET, 2011, 378 (9793) :771-784

[5] Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data [J].

Gaedigk, A ;

Gotschall, RR ;

Forbes, NS ;

Simon, SD ;

Kearns, GL ;

Leeder, JS .

PHARMACOGENETICS, 1999, 9 (06) :669-682

[6] The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen [J].

Goetz, Matthew P. ;

Knox, Stacey K. ;

Suman, Vera J. ;

Rae, James M. ;

Safgren, Stephanie L. ;

Ames, Matthew M. ;

Visscher, Daniel W. ;

Reynolds, Carol ;

Couch, Fergus J. ;

Lingle, Wilma L. ;

Weinshilboum, Richard M. ;

Fritcher, Emily G. Barr ;

Nibbe, Andrea M. ;

Desta, Zeruesenay ;

Nguyen, Anne ;

Flockhart, David A. ;

Perez, Edith A. ;

Ingle, James N. .

BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (01) :113-121

[7] Breast Cancer, Version 3.2018 Featured Updates to the NCCN Guidelines [J].

Goetz, Matthew P. ;

Gradishar, William J. ;

Anderson, Benjamin O. ;

Abraham, Jame ;

Aft, Rebecca ;

Allison, Kimberly H. ;

Blair, Sarah L. ;

Burstein, Harold J. ;

Dang, Chau ;

Elias, Anthony D. ;

Farrar, William B. ;

Giordano, Sharon H. ;

Goldstein, Lori J. ;

Isakoff, Steven J. ;

Lyons, Janice ;

Marcom, P. Kelly ;

Mayer, Ingrid A. ;

Moran, Meena S. ;

Mortimer, Joanne ;

O'Regan, Ruth M. ;

Patel, Sameer A. ;

Pierce, Lori J. ;

Reed, Elizabeth C. ;

Rugo, Hope S. ;

Sitapati, Amy ;

Smith, Karen Lisa ;

Smith, Mary Lou ;

Soliman, Hatem ;

Telli, Melinda L. ;

Ward, John H. ;

Young, Jessica S. ;

Shead, Dorothy A. ;

Kumar, Rashmi .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (02) :119-126

[8] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy [J].

Goetz, Matthew P. ;

Sangkuhl, Katrin ;

Guchelaar, Henk-Jan ;

Schwab, Matthias ;

Province, Michael ;

Whirl-Carrillo, Michelle ;

Symmans, W. Fraser ;

McLeod, Howard L. ;

Ratain, Mark J. ;

Zembutsu, Hitoshi ;

Gaedigk, Andrea ;

van Schaik, Ron H. ;

Ingle, James N. ;

Caudle, Kelly E. ;

Klein, Teri E. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) :770-777

[9]

Guoqiang Zhang, 2017, CHIN J BREAST, V11, P238

[10] Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China [J].

Lan, Bo ;

Ma, Fei ;

Chen, Shanshan ;

Wang, Wenna ;

Li, Qiao ;

Fan, Ying ;

Luo, Yang ;

Cai, Ruigang ;

Wang, Jiayu ;

Yuan, Peng ;

Zhang, Pin ;

Li, Qing ;

Xu, Binghe .

INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (10) :2499-2504

← 1 2 3 →